On the stock market since 2018, it operates in the world of health and science. It has 224 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 91% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
An investor who bought at the very peak is down 99% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 82% a year on average.
Sales run at $90.9M a year. A small number, but proof the product has real buyers.
A loss of $83.2M against $90.9M in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.02. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, DOCRF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: DOCRF is a high-risk stock — not yet profitable, and its future rides on its product catching on.